|
|
Prepublished online as a Blood First Edition Paper on September 12, 2002; DOI 10.1182/blood-2002-07-2305.
Previous Article | Table of Contents | Next Article 
Blood, 1 February 2003, Vol. 101, No. 3, pp. 807-814
CHEMOKINES
MIP-1 and MIP-1 differentially mediate mucosal and
systemic adaptive immunity
James W. Lillard Jr,
Udai P. Singh,
Prosper N. Boyaka,
Shailesh Singh,
Dennis D. Taub, and
Jerry R. McGhee
From the Department of Microbiology and Immunology,
Morehouse School of Medicine, Atlanta, GA; Department of Microbiology
and The Immunobiology Vaccine Center, University of Alabama at
Birmingham; and Laboratory of Immunology, National Institute on Aging,
Gerontology Research Center, Baltimore, MD.
Macrophage inflammatory protein-1 (MIP-1 ) and MIP-1 are
distinct but highly homologous CC chemokines produced by a variety of
host cells in response to various external stimuli and share affinity
for CCR5. To better elucidate the role of these CC chemokines in
adaptive immunity, we have characterized the affects of MIP-1 and
MIP-1 on cellular and humoral immune responses. MIP-1 stimulated strong antigen (Ag)-specific serum immunoglobulin G (IgG) and IgM
responses, while MIP-1 promoted lower IgG and IgM but higher serum
IgA and IgE antibody (Ab) responses. MIP-1 elevated Ag-specific IgG1
and IgG2b followed by IgG2a and IgG3 subclass responses, while MIP-1
only stimulated IgG1 and IgG2b subclasses. Correspondingly, MIP-1
produced higher titers of Ag-specific mucosal secretory IgA Ab levels
when compared with MIP-1 . Splenic T cells from MIP-1 -
or MIP-1 -treated mice displayed higher Ag-specific Th1 (interferon- [IFN- ]) as well as selective Th2 (interleukin-5 [IL-5] and IL-6) cytokine responses than did T cells from control groups. Interestingly, mucosally derived T cells from MIP-1 -treated mice displayed higher levels of IL-4 and IL-6 compared with
MIP-1 -treated mice. However, MIP-1 effectively enhanced
Ag-specific cell-mediated immune responses. In correlation with their
selective effects on humoral and cellular immune responses, these
chemokines also differentially attract CD4+ versus
CD8+ T cells and modulate CD40, CD80, and CD86 expressed by
B220+ cells as well as CD28, 4-1BB, and gp39 expression by
CD4+ and CD8+ T cells in a dose-dependent
fashion. Taken together, these studies suggest that these CC chemokines
differentially enhance mucosal and serum humoral as well as cellular
immune responses.

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
K. Shiraishi, Y. Ishiwata, K. Nakagawa, S. Yokochi, C. Taruki, T. Akuta, K. Ohtomo, K. Matsushima, T. Tamatani, and S. Kanegasaki
Enhancement of Antitumor Radiation Efficacy and Consistent Induction of the Abscopal Effect in Mice by ECI301, an Active Variant of Macrophage Inflammatory Protein-1{alpha}
Clin. Cancer Res.,
February 15, 2008;
14(4):
1159 - 1166.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Mummidi, L. M. Adams, S. E. VanCompernolle, M. Kalkonde, J. F. Camargo, H. Kulkarni, A. S. Bellinger, G. Bonello, H. Tagoh, S. S. Ahuja, et al.
Production of Specific mRNA Transcripts, Usage of an Alternate Promoter, and Octamer-Binding Transcription Factors Influence the Surface Expression Levels of the HIV Coreceptor CCR5 on Primary T Cells
J. Immunol.,
May 1, 2007;
178(9):
5668 - 5681.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Meagher, G. Arreaza, A. Peters, C. A. Strathdee, P. A. Gilbert, Q.-S. Mi, P. Santamaria, G. A. Dekaban, and T. L. Delovitch
CCL4 Protects From Type 1 Diabetes by Altering Islet {beta}-Cell-Targeted Inflammatory Responses
Diabetes,
March 1, 2007;
56(3):
809 - 817.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Meddows-Taylor, S. L. Donninger, M. Paximadis, D. B. Schramm, F. S. Anthony, G. E. Gray, L. Kuhn, and C. T. Tiemessen
Reduced ability of newborns to produce CCL3 is associated with increased susceptibility to perinatal human immunodeficiency virus 1 transmission
J. Gen. Virol.,
July 1, 2006;
87(7):
2055 - 2065.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Palaniappan, S. Singh, U. P. Singh, R. Singh, E. W. Ades, D. E. Briles, S. K. Hollingshead, W. Royal III, J. S. Sampson, J. K. Stiles, et al.
CCL5 Modulates Pneumococcal Immunity and Carriage
J. Immunol.,
February 15, 2006;
176(4):
2346 - 2356.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Duverger, R. J. Jackson, F. W. van Ginkel, R. Fischer, A. Tafaro, S. H. Leppla, K. Fujihashi, H. Kiyono, J. R. McGhee, and P. N. Boyaka
Bacillus anthracis Edema Toxin Acts as an Adjuvant for Mucosal Immune Responses to Nasally Administered Vaccine Antigens
J. Immunol.,
February 1, 2006;
176(3):
1776 - 1783.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S L-F Pender, V Chance, C V Whiting, M Buckley, M Edwards, R Pettipher, and T T MacDonald
Systemic administration of the chemokine macrophage inflammatory protein 1{alpha} exacerbates inflammatory bowel disease in a mouse model
Gut,
August 1, 2005;
54(8):
1114 - 1120.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. O. Ochiel, G. A. Awandare, C. C. Keller, J. B. Hittner, P. G. Kremsner, J. B. Weinberg, and D. J. Perkins
Differential Regulation of {beta}-Chemokines in Children with Plasmodium falciparum Malaria
Infect. Immun.,
July 1, 2005;
73(7):
4190 - 4197.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Yang, F. M. Murillo, M. J. Delannoy, R. L. Blosser, W. H. Yutzy IV, S. Uematsu, K. Takeda, S. Akira, R. P. Viscidi, and R. B. S. Roden
B Lymphocyte Activation by Human Papillomavirus-Like Particles Directly Induces Ig Class Switch Recombination via TLR4-MyD88
J. Immunol.,
June 15, 2005;
174(12):
7912 - 7919.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Capelli, A. Di Stefano, I. Gnemmi, and C. F. Donner
CCR5 expression and CC chemokine levels in idiopathic pulmonary fibrosis
Eur. Respir. J.,
April 1, 2005;
25(4):
701 - 707.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Kobayashi, T. Kohda, K. Kataoka, H. Ihara, S. Kozaki, D. W. Pascual, H. F. Staats, H. Kiyono, J. R. McGhee, and K. Fujihashi
A Novel Neurotoxoid Vaccine Prevents Mucosal Botulism
J. Immunol.,
February 15, 2005;
174(4):
2190 - 2195.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
U. P. Singh, S. Singh, P. N. Boyaka, J. R. McGhee, and J. W. Lillard Jr
Granulocyte chemotactic protein-2 mediates adaptive immunity in part through IL-8R{beta} interactions
J. Leukoc. Biol.,
December 1, 2004;
76(6):
1240 - 1247.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
U. P. Singh, S. Singh, P. Ravichandran, D. D. Taub, and J. W. Lillard Jr.
Viral Macrophage-Inflammatory Protein-II: A Viral Chemokine That Differentially Affects Adaptive Mucosal Immunity Compared with Its Mammalian Counterparts
J. Immunol.,
November 1, 2004;
173(9):
5509 - 5516.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Punturieri, R. S. Alviani, T. Polak, P. Copper, J. Sonstein, and J. L. Curtis
Specific Engagement of TLR4 or TLR3 Does Not Lead to IFN-{beta}-Mediated Innate Signal Amplification and STAT1 Phosphorylation in Resident Murine Alveolar Macrophages
J. Immunol.,
July 15, 2004;
173(2):
1033 - 1042.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. W. DePaolo, R. Lathan, and W. J. Karpus
CCR5 Regulates High Dose Oral Tolerance by Modulating CC Chemokine Ligand 2 Levels in the GALT
J. Immunol.,
July 1, 2004;
173(1):
314 - 320.
[Abstract]
[Full Text]
[PDF]
|
 |
|
| |